IDV vehicle
36E79721D0016
NEW AWARD FOR AMBRISENTAN TABLETS. PERIOD OF PERFORMANCE IS APRIL 1, 2021 - MARCH 31, 2022 WITH FOUR ONE-YEAR OPTIONS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | NAC PHARMACEUTICALS (36E797) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $9.5M |
| Start date | Apr 1, 2021 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | May 27, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 27, 2025 | P00011 | $0 | INCORPORATION OF 2025 SMALL BUSINESS SUBCONTRACTING PLAN FOR CIPLA USA, INC. THE PLAN IS EFFECTIVE 4/1/2025 - 3/31/2026. |
| Feb 18, 2025 | P00010 | $0 | EXERCISE OPTION YEAR 4, EFFECTIVE APRIL 1, 2025 TO MARCH 31, 2026 FOR AMBRISENTAN TABLETS WITH CIPLA USA, INC. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.